Heart Disease Trial, Recruiting NCT02744677 Sponsor: Edwards Lifesciences Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT02744677
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who weigh at least 20 kg (44 lbs)
  • People who have a failing or poorly functioning conduit or previously implanted valve in the pulmonary (right side of the heart) position that needs treatment, and whose anatomy falls within the size range required by the device
  • People who have at least a moderate level of a leaky pulmonary valve and/or significant blockage of blood flow through the right side of the heart
  • People who have been fully informed about the study and have given written consent to participate (or had a legal representative do so on their behalf)

Who may not be able to join:

  • People who currently have an active infection requiring antibiotic treatment (though eligibility may be reconsidered two weeks after finishing antibiotics)
  • People who have had or currently have an infection of the heart (endocarditis) within the past 180 days
  • People with low white blood cell counts, low red blood cell counts, low platelet counts, or any known blood clotting disorder
  • People whose anatomy is not suitable for the device to be delivered through the groin (femoral) blood vessel
  • People who need other heart procedures done at the same time, except for certain procedures on the pulmonary arteries
  • People whose imaging shows that placing the new valve could squeeze or compress the coronary arteries (blood vessels supplying the heart)
  • People who have had a heart-related procedure or surgery within the 30 days before this procedure
  • People who have any surgery or heart-related procedure planned within 30 days after this procedure
  • People with a current or past history of intravenous drug use
  • People with a serious non-heart-related illness where life expectancy is less than one year
  • People with a known allergy to aspirin or heparin who cannot safely take alternative blood-thinning medications
  • People with a known allergy to cobalt-chromium, nickel, or contrast dye used in imaging, if that allergy cannot be adequately managed beforehand
  • People currently enrolled in another clinical trial that has not yet completed its main study goals
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: D. Scott Lim, MD, University of Virginia Medical Center

Phone: (949) 250-2500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Edwards Lifesciences
Registry
ClinicalTrials.gov
Start date
5 July 2016
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

THV dysfunction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov